Key facts
- Notable investors include TusStar Incubator, Fangxin Capital, Qirong Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Guanzhan Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Guanzhan Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Guanzhan Bioscience
Developer of biomedical research tools designed for experimental and clinical investigation purposes. The company offers to focus on early-stage medical research and trial development, integrating laboratory-based methodologies, data-driven experimental design, and regulatory-aligned documentation processes, enabling the life sciences and healthcare research market to conduct foundational studies, validate hypotheses, and support translational research through structured and compliant scientific workflows.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Guanzhan Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Guanzhan Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Guanzhan Bioscience in its N-PORT filings yet. We sweep new filings monthly.